72.11.Z - Research and experimental development on biotechnology
62.01.Z - Computer programming activities
70.22.Z - Business and other management consultancy activities
71.20.B - Other technical testing and analysis
72.19.Z - Other research and experimental development on natural sciences and engineering
73.11.Z - Advertising agencies activities
74.90.Z - Other professional, scientific and technical activities not elsewhere classified
77.40.Z - Leasing of intellectual property and similar products, except copyrighted works
84.12.Z - Regulation of the activities of providing health care, education, cultural services and other social services, excluding social security
85.60.Z - Educational support activities
2021 | 2022 | 2023 | ||
---|---|---|---|---|
K PLN | K PLN | K PLN | % | |
Gross profit (loss) | 68 | -74,5 | 112,2 | 250,5 |
EBITDA | 73,2 | -72,2 | 117,4 | 262,5 |
Short time liabilities | 24 | 11,9 | 43,7 | 266,4 |
Equity capital | 9,7 | -64,8 | 47,4 | 173,1 |
Operating profit (EBIT) | 73,2 | -72,2 | 117,4 | 262,5 |
Assets | 183,7 | 49,1 | 193,1 | 293,3 |
Net profit (loss) | 68 | -74,5 | 112,2 | 250,5 |
Cash | 164,8 | 25,2 | 1,8 | -92,7 |
Net income from sale | 370,9 | 37,3 | 317,4 | 749,9 |
Liabilities and provisions for liabilities | 174 | 113,9 | 145,7 | 27,9 |
Working assets | 178 | 43,4 | 187,4 | 331,8 |
Depreciation | 0 | 0 | 0 | 0 |
% | % | % | p.p. | |
Profitability of capital | 699,6 | 115 | 236,9 | 121,9 |
Equity capital to total assets | 5,3 | -132,1 | 24,5 | 156,6 |
Gross profit margin | 18,3 | -199,6 | 35,4 | 235 |
EBITDA Margin | 19,7 | -193,4 | 37 | 230,4 |
Days | Days | Days | Days | |
Short term commitment turnover cycle | 24 | 117 | 50 | -67 |
Current financial liquidity indicator | 7.418848514556885 | 3.6375956535339355 | 4.286983013153076 | 0,7 |
Net dept to EBITDA | -0.20273880660533905 | -1.0638470649719238 | 0.8535751104354858 | 2 |
Opinie dotyczące usług, produktów oraz działalności firmy nie są weryfikowane